. Author manuscript; available in PMC: 2022 Sep 28.

Published in final edited form as: Eur J Cancer. 2021 Jan 16;145:132–142. doi: 10.1016/j.ejca.2020.12.008

Table 4.

Factors impacting hazard ratio for PFS in the PDGFRA D842V population.

Parameter	HR	95% CI	P value

Age	1.05	0.99–1.11	0.086
Sex	1.42	0.54–3.73	0.479
Avapritinib dose^a	0.69	0.53–0.89	0.005
Prior TKI	0.34	0.10–1.13	0.077
ECOG PS	6.09	2.36–15.74	< 0.001

CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; HR, hazard ratio; QD, once daily; TKI, tyrosine kinase inhibitor. Bold values are statistically significant P values.

50 mg QD dose increments assessed continually for each patient throughout the treatment period.